Drug intelligence / Profile preview

Nephropathy Formula No. 1

Development stage: Phase 1
Administration: Oral

Overview

Nephropathy Formula No. 1 appears to be a non-standardized, possibly traditional or alternative medicine product intended for the management or support of kidney health, particularly nephropathies (kidney diseases). There is no evidence in the provided sources or major medical databases that this is an FDA-approved pharmaceutical drug, nor is there information on its specific composition, mechanism of action, clinical trial status, or regulatory approval as a conventional medication. It may be marketed as a dietary supplement or herbal formula rather than a prescription drug.

Brand names: Nephropathy Formula No. 1
Other names: Nephropathy Formula No. 1

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)IL-6 (Interleukin 6)

Beyond the preview

Go deeper on Nephropathy Formula No. 1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nephropathy Formula No. 1.

Explore the full profile